Biomarker Discovery in Complex Disease States: Sample Selection Strategies Across Specimen Types

Photo Credit: CDC/ Renelle Woodall

Biomarker discovery is one of the most important frontiers in translational medicine. It bridges basic disease mechanisms and the clinical diagnostic tools that improve patient outcomes. Molecular signatures can predict disease risk, diagnose conditions earlier, stratify patients, or track treatment response. Finding them depends fundamentally on the quality and fit of the biospecimens researchers analyze.

Human biology is complex, spanning countless molecular species across genomic, transcriptomic, proteomic, and metabolomic layers. That complexity calls for strategic specimen selection, matched precisely to your research goals and analytical platforms.

The specimen type you choose shapes which molecules you can detect and the dynamic range of your measurement platforms. Ultimately, it determines what biological insights come out of costly discovery campaigns. Human Plasma gives access to circulating proteins, metabolites, and cell-free nucleic acids released from distant tissues — a liquid biopsy window into systemic disease. Human Serum contains clot-derived proteins absent from plasma, enriching certain analyte classes while depleting coagulation factors. Human PBMCs enable cellular phenotyping, functional assays, and single-cell analyses that reveal immune changes invisible in acellular biofluids.

At Sanguine, our portfolio spans cellular and fluid matrices, combined with detailed genomic annotation from 70,000+ donors across the United States. This breadth lets researchers pick the specimen type that best fits their specific biomarker discovery goals.

Strategic Framework for Specimen Type Selection

The basic choice between cellular and acellular biospecimens comes down to where candidate biomarkers live: in cells, secreted into circulation, or both. Cytokines are a good example of molecules that exist in multiple compartments. Cells make them, secrete them into local microenvironments, and release them into systemic circulation at varying concentrations.[1] Choosing the right specimen type means understanding which biological compartment gives the clearest signal while minimizing pre-analytical confounders.

Acellular biofluids like Human Plasma and Human Serum offer clear advantages for circulating biomarker discovery. Their proteome is less complex than tissue lysates, which makes it easier to find low-abundance proteins by mass spectrometry or aptamer-based platforms.[2] Standard venipuncture supports longitudinal sampling to track disease progression or treatment response. Done properly, cryopreservation keeps proteins and metabolites stable for years, supporting retrospective case-control studies and biobank-based discovery.

But plasma and serum have real challenges. Plasma proteins span a 10,000-fold concentration range, from albumin at 40 mg/mL down to cytokines at pg/mL. This requires depletion strategies or high-sensitivity assays to find rare species.[3] Pre-analytical variables — tube type, processing delays, centrifugation protocol, freeze-thaw cycles — dramatically affect analyte stability and reproducibility. Telling true disease biomarkers apart from pre-analytical artifacts requires strict quality control and standardized processing.

Cellular biospecimens, including Human PBMCs, Human Whole Blood, and Human Leukopak preparations, offer complementary approaches. Single-cell transcriptomics reveals cellular diversity and rare populations that bulk analysis would miss.[4] Functional assays identify mechanistic biomarkers that reflect actual disease biology, not just association. Immunophenotyping quantifies cell subset frequencies that shift in disease and carry diagnostic or prognostic value.

Specialized specimens extend discovery beyond peripheral blood. Human Synovial Fluid gives direct access to joint inflammation biomarkers in rheumatoid arthritis and osteoarthritis. Protein concentrations there reflect local disease activity more sensitively than systemic markers.[5] Tissue biopsies support spatial transcriptomics and proteomics that preserve the anatomical context needed to understand tumor microenvironments or organ-specific disease.

Plasma vs. Serum: Navigating Critical Selection Criteria

Choosing plasma versus serum is one of the most consequential calls in biofluid biomarker discovery. The right answer depends on which analytes you care about and which analytical platforms you’re using. Human Plasma collected with anticoagulants (EDTA, citrate, or heparin) prevents clotting, preserving coagulation factors and limiting the platelet activation that releases proteins and bioactive molecules.[6] This stability matters especially for cytokine measurements, where platelet-derived factors can artificially inflate serum concentrations above true circulating levels.

Human Serum preparation involves intentional clotting before centrifugation, which depletes fibrinogen and other coagulation proteins while enriching growth factors released during clotting. That introduces biological variability tied to clotting time, temperature, and separation timing.[7] Still, serum has advantages for certain immunoassays optimized against serum reference ranges, and some analytes stay more stable in serum than in plasma.

Anticoagulant choice adds more complexity. EDTA binds divalent cations (calcium, magnesium) needed for many enzymatic reactions and can interfere with metal-dependent assays.[8] Citrate dilutes specimens by 10%, requiring concentration adjustments. Heparin inhibits PCR at collection-tube concentrations, ruling out certain nucleic acid analyses. Matching the anticoagulant to your downstream platform avoids costly discovery failures from assay incompatibility.

Proteomic differences between plasma and serum go beyond coagulation factors — platelet activation and clotting affect many other proteins too. Mass spectrometry finds hundreds of proteins that differ between matched plasma and serum from the same people.[9] A candidate discovered in one matrix may not validate in the other, so keep your specimen type consistent across discovery, validation, and clinical translation.

Pre-analytical standardization often matters more than specimen type itself. Variation in processing time, centrifugation g-force and duration, storage temperature, and freeze-thaw cycles can introduce more variability than the actual biological difference between disease and control groups.[10] Sanguine’s standardized protocols minimize these confounders. Detailed genomic annotation documents every step from phlebotomy through cryopreservation, so researchers can account for whatever variables remain.

Cellular Biospecimens for Multi-Omics Discovery

Human PBMCs are the cellular workhorse for immune-focused biomarker discovery. They give access to lymphocyte and monocyte populations whose frequencies, phenotypes, and functional states shift dramatically in disease. Single-cell RNA sequencing of PBMCs from disease cohorts reveals disease-specific cell states, altered differentiation paths, and novel populations rare in healthy controls.[11] These cellular biomarkers often connect signals directly to disease biology.

Cryopreservation supports retrospective discovery using biobanked PBMC collections, with hundreds of thousands of annotated specimens available from cohort studies and clinical trials. Post-thaw viability above 85% keeps specimens intact for flow cytometry, bulk RNA sequencing, and many functional assays.[12] Single-cell technologies are more sensitive to cryopreservation artifacts, so telling apart true biomarkers from freeze-thaw effects requires matched fresh and frozen controls.

Human Whole Blood offers unique advantages for RNA-based discovery. Its expression signatures reflect recent cellular activation and stay stable for 24 hours in the right RNA preservation tubes.[13] Whole blood transcriptomic signatures show diagnostic and prognostic value across infectious diseases, autoimmune conditions, and cancer. Since collection is simple, it’s easier to translate into point-of-care or clinical laboratory tests.

The cellular mix in whole blood and PBMCs requires either computational deconvolution to infer cell-type-specific signals from bulk data, or single-cell approaches that measure each cell directly.[14] Cell-type proportions vary across people and disease states, which confounds bulk measurements. Flow cytometry counting or deconvolution algorithms help separate changed cell frequencies from per-cell expression changes.

Large-scale collections like Human Leukopak preparations enable cell-type-specific isolation you can’t get from a standard draw. Magnetic bead sorting, FACS, or density gradient separation enrich specific populations for focused discovery.[15] This targeted approach cuts sample complexity, enriches rare populations, and enables deeper profiling of the cell-type-specific changes driving disease.

Pre-Analytical Variables: The Hidden Determinants of Reproducibility

Pre-analytical variables — the many factors that affect specimens between collection and analysis — are the most common cause of biomarkers failing to reproduce. Temperature swings, processing delays, inconsistent centrifugation, poor storage, or freeze-thaw cycles introduce molecular changes that can exceed disease-related changes.[16] Candidates found using poorly controlled specimens often fail to validate in cohorts with different pre-analytical conditions.

Hemolysis — the rupture of red cells that releases their contents — is one of the most problematic variables for plasma and serum discovery. Even mild hemolysis (free hemoglobin as low as 0.2 g/L) changes measurements of potassium, lactate dehydrogenase, and aspartate aminotransferase.[17] Proteomic and metabolomic analyses show hundreds of hemolysis-related changes, with contaminating intracellular material masquerading as disease biomarkers in poorly controlled studies.

Standardized Operating Procedures for collection, processing, and storage are essential infrastructure. The Biospecimen Reporting for Improved Study Quality (BRISQ) guidelines list the critical variables to document and control.[18] Minimum documentation includes processing time from venipuncture to cryopreservation, centrifugation parameters, storage temperature, freeze-thaw history, and fasting status. Sanguine tracks all pre-analytical variables with electronic records that accompany every specimen.

Batch effects — systematic technical variation when specimens are processed or analyzed in separate batches — confound discovery when batch assignment lines up with case-control status. If you process all disease samples in one batch and controls in another, you can no longer tell disease effects apart from batch effects.[19] Randomized processing, balanced batch designs, and statistical correction all help. Our prospective collection services support batch-balanced designs.

Pre-analytical variables affect each analyte class differently, so controls need to be class-specific. RNA degrades fast at room temperature and needs immediate stabilization or cold storage. Proteins stay relatively stable but are vulnerable to proteolysis during delays. Metabolites vary widely, with some changing within minutes.[20] Understanding analyte-specific stability shapes specimen selection and acceptable processing timelines.

Critical Pre-Analytical Factors in Sample Selection

Systematically checking pre-analytical parameters protects your discovery investment from technical confounders. The framework below guides quality-focused procurement.

Collection Timing and Clinical Context

Disease State Definition:

• Precise disease duration documentation (days since symptom onset)
• Disease stage classification using validated staging systems
• Treatment-naive vs. treatment-experienced status clearly defined
• Comorbidity documentation affecting systemic biology
• Acute exacerbation vs. stable disease state
• Fasting status for metabolic biomarker studies
• Time of day for circadian-influenced analytes
• Medication timing relative to blood draw

Longitudinal Collection Parameters:

• Consistent collection timepoints across subjects
• Baseline pre-diagnosis specimens when available
• Serial sampling intervals matched to disease kinetics
• Paired pre/post-treatment specimens for response biomarkers
• Long-term follow-up specimens for prognostic marker validation
• Matched specimens from flare and remission states
• Collection protocols accounting for diurnal variation
• Standardized interval from last meal for metabolic studies

Processing and Preservation Standards

Temperature Control and Processing Timing:

• Time from venipuncture to processing start (target <2 hours)
• Sample temperature maintenance during transport (2-8°C)
• Centrifugation parameters (g-force, duration, temperature) specified
• Processing environment temperature monitoring
• Time from processing to cryopreservation documented
• Controlled-rate freezing protocols when applicable
• Storage temperature verification with continuous monitoring
• Maximum storage duration before analysis specified

Quality Assessment and Documentation:

• Hemolysis index measurement and acceptance criteria (<0.5 g/L)
• Lipemia assessment via optical measurement
• Icterus quantification when clinically relevant
• Platelet count documentation for plasma specimens
• Cell viability quantification for cellular products
• Bacterial/fungal contamination screening
• pH and osmolality for specialized applications
• Visual inspection with photographic documentation

Aliquoting and Storage Strategies:

• Single-use aliquots preventing freeze-thaw cycles
• Aliquot volumes matched to assay requirements
• Cryovial material compatible with storage temperature
• Freeze-thaw cycle tracking for each aliquot
• Storage location documentation enabling rapid retrieval
• Backup aliquots secured for invaluable specimens
• Storage buffer/media composition documented
• Nitrogen vapor vs. liquid phase specified

Anticoagulant Selection and Effects:

• EDTA for DNA/RNA applications and general proteomics
• Citrate when calcium-dependent processes studied
• Heparin for most plasma protein measurements (avoid for PCR)
• Specialized anticoagulants for specific applications (e.g., ACD for cell separations)
• Anticoagulant concentration verification
• Effects on downstream assay performance validated
• Consistency maintained across all study specimens
• Compatibility with all planned analytical platforms confirmed

Multi-Omics Biomarker Discovery: Quality Requirements Across Technologies

Combining genomic, transcriptomic, proteomic, and metabolomic data promises a full molecular picture of disease. But successful multi-omics discovery demands specimen quality that meets the strictest requirements of every technology involved. Feeding multiple platforms from a single specimen removes person-to-person variation, but it needs careful QC and enough volume for every planned analysis.

Transcriptomic discovery using bulk RNA sequencing or microarrays needs RNA integrity numbers (RIN) above 7 for accurate quantification; RIN below 6 introduces systematic bias.[21] Single-cell RNA sequencing is even more sensitive, needing RIN above 7 and minimal ambient RNA contamination. Our Human Whole Blood collections in RNA preservation tubes maintain RIN scores above 8 under standardized protocols.

Proteomic discovery spans targeted immunoassays and mass spectrometry that measures thousands of proteins at once. Sample requirements vary a lot across these methods. ELISA and multiplex bead assays tolerate some pre-analytical variation and can use specimens that mass spectrometry would reject.[22] Discovery-phase mass spectrometry needs pristine specimens with minimal degradation, since proteolytic fragments complicate peptide identification.

Metabolomics is especially sensitive to pre-analytical variables, since metabolites turn over fast and enzymatic activity continues during processing. Blood glucose drops within minutes at room temperature as glycolysis proceeds; lactate rises during processing delays.[23] Immediate cooling, rapid processing, and enzyme-inhibitor additives minimize these artifacts. Sanguine’s temperature-controlled logistics and documented timelines support confident metabolomic discovery.

Cell-free DNA (cfDNA) is an emerging biomarker class with its own requirements. Its fragmentation pattern, concentration, and sequence composition inform cancer, prenatal testing, and transplant monitoring.[24] Specialized tubes with cellular preservatives prevent white-cell lysis that would dilute the cfDNA signal. Delays as short as 6 hours increase genomic DNA contamination. Our custom protocols accommodate cfDNA-specific requirements for liquid biopsy development.

Essential Quality Parameters for Multi-Omics Studies

Systematically checking quality across specimen cohorts protects multi-omics investments from artifacts that hurt sensitivity and validation. The parameters below are minimum standards.

RNA Quality and Cellular Integrity Metrics

RNA Preservation and Integrity:

• RIN scores ≥7 for bulk RNA sequencing applications
• RIN scores ≥8 for single-cell RNA sequencing
• 260/280 absorbance ratios 1.8-2.0 indicating protein absence
• 260/230 absorbance ratios >1.8 indicating chemical contaminant absence
• Total RNA yield sufficient for planned experiments plus repeats
• Mitochondrial RNA percentage <20% for scRNA-seq
• Hemoglobin RNA transcripts absent (no hemolysis)
• Ribosomal RNA integrity verified before transcriptome library construction

Cellular Sample Quality Indicators:

• Cell viability ≥85% by trypan blue or flow cytometry
• Doublet rate <5% for single-cell preparations
• Cell size distribution normal for cell type
• Expression of housekeeping genes at expected levels
• Absence of stress response gene activation signatures
• Nuclear integrity for snRNA-seq applications
• Cell membrane integrity by propidium iodide exclusion
• Functional validation in representative specimens

Protein Analyte Stability and Sample Quality

Proteomic Sample Quality Standards:

• Hemolysis index <0.5 g/L free hemoglobin
• Lipemia assessment with turbidity correction if needed
• Total protein concentration within expected ranges (60-80 g/L for plasma)
• Albumin and IgG concentrations normal (primary QC markers)
• Complement activation products absent (C3a, C5a)
• Protease inhibitor cocktails added when proteolytic degradation risks high
• Western blot validation of intact target proteins
• Mass spectrometry peptide coverage for proteins of interest

Pre-Analytical Stability Verification:

• Freeze-thaw cycle limit defined and tracked (<3 cycles typical)
• Storage duration at -80°C documented (most proteins stable ≥2 years)
• Protein degradation assessment via capillary electrophoresis
• Comparison to fresh specimen controls when feasible
• Stability testing for novel biomarker candidates
• Temperature excursion event documentation and impact assessment
• Batch-to-batch reference standard measurements
• Internal standard spike-ins for quality control

Metabolite and Small Molecule Quality Control

Metabolomic Quality Indicators:

• Hemolysis markers (intracellular metabolites) at expected low levels
• Processing time <30 minutes for labile metabolites
• Sample pH within physiological range (7.35-7.45)
• Known stable metabolites at expected concentrations
• Absence of oxidation products in sensitive classes
• EDTA and citrate anticoagulant effects characterized
• Quality control pooled samples for inter-batch normalization
• Metabolite stability validation for specific preservation methods

Cell-Free Nucleic Acid Integrity:

• cfDNA fragment size distributions characteristic (140-170 bp peak)
• Absence of genomic DNA contamination (large fragments)
• cfDNA concentration within expected ranges (<100 ng/mL normal)
• Using blood collection tubes with cellular preservatives
• Processing <6 hours to prevent leukocyte lysis
• Centrifugation optimized to remove cellular debris without cfDNA loss
• cfRNA integrity assessment by bioanalyzer
• Spike-in controls for extraction efficiency validation

Specimen Annotation and Metadata Completeness

Clinical Phenotype Documentation:

• Physician-confirmed diagnoses with ICD-10 codes
• Diagnostic test results supporting phenotype classification
• Disease duration calculated from symptom onset or diagnosis date
• Disease severity scores using validated scales
• Treatment history including doses and administration routes
• Laboratory values proximate to specimen collection
• Imaging results when disease assessment relevant
• Validated patient-reported outcome measures

Matched Specimen Availability:

• Paired specimens from multiple timepoints available
• Matched tissue and blood specimens when applicable
• DNA from same individual for genomic correction
• Family member specimens for heritability studies
• Pre/post-treatment paired collections
• Technical replicate aliquots for reproducibility assessment
• Sufficient volume for discovery and validation cohorts
• Longitudinal specimens spanning disease natural history

Biomarker Discovery Strategies for Hematological Diseases

Hematological disease biospecimens present unique opportunities and challenges, since the diseased tissue itself is accessible through peripheral blood. Leukemias, lymphomas, and myelodysplastic syndromes involve malignant transformation of blood cells themselves. This makes Human PBMCs, Human Whole Blood, and Human Leukopak preparations ideal for direct tumor profiling.[25]

The clonal architecture of these malignancies — with multiple competing clones evolving over time and treatment — calls for serial collection that captures disease dynamics. Baseline pre-treatment specimens, on-treatment monitoring samples, and relapse biospecimens together support a full picture of response and resistance.[26] Biomarkers that predict response, detect minimal residual disease, and give early relapse warning are clinically valuable across hematological cancers. Sanguine’s longitudinal collection capabilities support these designs.

Benign hematological disorders, such as anemia, clotting disorders, and immune cytopenias, also benefit from blood-based approaches. Plasma and serum contain erythropoietin, coagulation factors, autoantibodies, and other proteins that reflect disease biology.[27] Cellular analyses reveal abnormal red-cell shape, altered platelet function, or disrupted immune development. The challenge is telling primary drivers apart from secondary compensatory responses, which requires well-phenotyped cohorts.

Inflammatory conditions like hemolytic anemias show why pre-analytical control matters so much. Disease-related hemolysis releases intracellular contents into plasma/serum, but rough handling can cause identical changes through accidental hemolysis.[28] Strict hemolysis-index measurement and exclusion criteria prevent mistaking artifacts for biomarkers. Our standardized protocols minimize mechanical hemolysis while measuring free hemoglobin, so researchers can exclude compromised specimens.

Genomic changes drive many hematological malignancies, which makes DNA from Human PBMCs or Human Leukopak valuable for mutation detection, copy number analysis, and minimal residual disease monitoring. Cell-free DNA from Human Plasma offers non-invasive tumor monitoring, since malignant cells release mutant DNA fragments as they die.[29] Combining cellular and cfDNA approaches gives complementary information about disease burden, clonal diversity, and response over time.

Rare Disease Biomarker Discovery: Navigating Small Sample Challenges

Rare disease biospecimens present unique challenges: limited patient numbers, varied presentations, and often unclear mechanisms. Standard power calculations become impractical when an entire disease population numbers in the hundreds or thousands globally. Alternative designs — n-of-1 studies, longitudinal within-individual profiling, or mechanistic biomarkers grounded in disease biology — tend to work better.[30]

The rarity of specimens from ultra-rare diseases (<1 per million) raises the stakes for quality and annotation. Since these specimens are irreplaceable, they demand pristine quality to get the most information from them and avoid wasted analyses. Thorough annotation lets researchers match specimens to appropriate controls and understand variability within small cohorts.[31] Sanguine’s access to 70,000+ donors includes people with rare genetic, metabolic, and orphan disease diagnoses often left out of other collections.

Multi-omic profiling is especially valuable in rare disease, where hypothesis-free discovery can uncover unexpected pathways and targets. A patient may carry variants in genes of unknown function; combined transcriptomic and metabolomic analysis can shed light on the downstream effects.[32] Paired Human PBMCs, Human Plasma, and Human Serum from the same people support these integrative approaches.

Natural history studies benefit from longitudinal collection that tracks progression over months to years. Biomarkers that predict when a complication will start, document the disease trajectory, or measure treatment response are valuable even when patient numbers rule out large validation cohorts.[33] These mechanistic biomarkers often carry over across disease boundaries when common pathways are involved. Custom prospective collection services accommodate the extended timelines and flexible scheduling that rare disease studies need.

International collaboration boosts statistical power but introduces standardization challenges across sites and countries. Harmonized protocols, centralized processing, pre-analytical quality monitoring, and thorough metadata make productive collaboration possible.[34] Sanguine’s geographic reach across the United States and standardized SOPs position us as centralized collection infrastructure for multi-site rare disease studies.

Quality Control Strategies for Large-Scale Discovery Cohorts

Cohorts spanning hundreds to thousands of specimens need systematic QC to prevent batch effects and catch problem specimens before expensive analyses consume irreplaceable material. Pooled “super samples,” which combine small aliquots from many specimens, serve as technical replicates spread across batches, enabling normalization and batch correction.[35]

Pilot quality checks using representative specimens from each group catch pre-analytical issues before you commit an entire cohort. Measuring standard clinical values (CBCs, chemistry panels), quantifying hemolysis, and checking RNA integrity in pilots lets researchers spot and fix issues early.[36] These checks typically cost less than 5% of a study’s budget, but they prevent major failures that would otherwise waste irreplaceable specimens.

Hierarchical clustering and principal component analysis on genome-wide data serve as after-the-fact QC, spotting outliers driven by technical artifacts rather than biology. Specimens that cluster by batch, processing date, or storage duration rather than disease status flag batch effects that need correction or exclusion.[37] These unsupervised analyses catch issues that standard QC would miss. Our thorough pre-analytical documentation lets researchers annotate molecular data with all the technical variables, which helps with spotting and correcting artifacts.

Sanguine’s Integrated Biomarker Discovery Solutions

Our end-to-end support spans specimen-selection consultation through delivery of quality-controlled, fully annotated biospecimens that meet the requirements of modern multi-omic platforms. Direct relationships with 70,000+ donors across the United States give access to hematological disease biospecimens, rare disease biospecimens, and diverse population cohorts that support generalizable discovery.[38]

Standardized collection and processing minimize pre-analytical variation, while detailed genomic annotation documents every variable that could affect quality or molecular readouts. From study design to receipt of samples, our scientific team works with researchers to optimize specimen types, collection strategies, and QC parameters.[39] Custom prospective collection accommodates longitudinal designs, matched-specimen strategies, and specialized processing unique to specific biomarker classes or platforms.

Temperature-controlled logistics keep the cold chain intact with real-time tracking. Certificates of analysis documenting all QC accompany shipments, so researchers can exclude problematic specimens or stratify results by quality metrics. Our ISO-certified quality management systems keep results consistent, reproducible, and regulatory-compliant, supporting biomarker validation toward diagnostic development.

---

Check Our Inventory

Ready to accelerate your biomarker discovery program with premium-quality biospecimens?

Explore our comprehensive inventory of hematological disease biospecimens and rare disease biospecimens today. Our scientific specialists can discuss your specific biomarker discovery goals and recommend the right specimen selection strategy.

Request a Custom Quote →

---

Ethical Sourcing and Regulatory Compliance

All Sanguine biospecimens are collected under IRB-approved protocols with full informed consent from every donor. Our HIPAA-compliant data management systems protect donor privacy while giving researchers access to detailed genomic annotation for their studies. We maintain ISO 9001:2015 and ISO 13485:2016 certifications, reflecting our commitment to quality management across all operations.

Donor compensation follows ethical guidelines set by professional societies, ensuring voluntary participation without coercion. Geographic diversity in our collection network across the United States supports health equity in research while giving access to populations often left out of biomedical studies. Every specimen is designated Research Use Only (RUO) with clear documentation of its intended application scope.

---

References

1. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8(8):457-465. doi:10.1038/nrendo.2012.49
2. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002;1(11):845-867. doi:10.1074/mcp.r200007-mcp200
3. Hortin GL, Sviridov D, Anderson NL. High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. Clin Chem. 2008;54(10):1608-1616. doi:10.1373/clinchem.2008.108175
4. Papalexi E, Satija R. Single-cell RNA sequencing to explore immune cell heterogeneity. Nat Rev Immunol. 2018;18(1):35-45. doi:10.1038/nri.2017.76
5. Lotz M, Martel-Pelletier J, Christiansen C, et al. Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis. 2013;72(11):1756-1763. doi:10.1136/annrheumdis-2013-203726
6. Drake SK, Bowen RA, Remaley AT, Hortin GL. Potential interferences from blood collection tubes in mass spectrometric analyses of serum polypeptides. Clin Chem. 2004;50(12):2398-2401. doi:10.1373/clinchem.2004.040303
7. Tuck MK, Chan DW, Chia D, et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res. 2009;8(1):113-117. doi:10.1021/pr800545q
8. Cheng S, Netea MG, Joosten LAB. The interplay between central metabolism and innate immune responses. Cytokine Growth Factor Rev. 2014;25(6):707-713. doi:10.1016/j.cytogfr.2014.06.008
9. Hsieh SY, Chen RK, Pan YH, Lee HL. Systematical evaluation of the effects of sample collection procedures on low-molecular-weight serum/plasma proteome profiling. Proteomics. 2006;6(10):3189-3198. doi:10.1002/pmic.200500535
10. Betsou F, Lehmann S, Ashton G, et al. Standard preanalytical coding for biospecimens: defining the sample PREanalytical code. Cancer Epidemiol Biomarkers Prev. 2010;19(4):1004-1011. doi:10.1158/1055-9965.EPI-09-1268
11. Stephenson E, Reynolds G, Botting RA, et al. Single-cell multi-omics analysis of the immune response in COVID-19. Nat Med. 2021;27(5):904-916. doi:10.1038/s41591-021-01329-2
12. Ramachandran H, Laux J, Moldovan I, et al. Optimal thawing of cryopreserved peripheral blood mononuclear cells for use in high-throughput human immune monitoring studies. Cells. 2012;1(3):313-324. doi:10.3390/cells1030313
13. Debey S, Schoenbeck U, Hellmich M, et al. Comparison of different isolation techniques prior gene expression profiling of blood derived cells: impact on physiological responses, on overall expression and the role of different cell types. Pharmacogenomics J. 2004;4(3):193-207. doi:10.1038/sj.tpj.6500240
14. Newman AM, Steen CB, Liu CL, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773-782. doi:10.1038/s41587-019-0114-2
15. Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol. 2012;12(3):191-200. doi:10.1038/nri3158
16. Lippi G, Salvagno GL, Montagnana M, Franchini M, Guidi GC. Venous stasis and routine hematologic testing. Clin Lab Haematol. 2006;28(5):332-337. doi:10.1111/j.1365-2257.2006.00818.x
17. Moore HM, Kelly AB, Jewell SD, et al. Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol. 2011;119(2):92-101. doi:10.1002/cncy.20147
18. Leek JT, Scharpf RB, Bravo HC, et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet. 2010;11(10):733-739. doi:10.1038/nrg2825
19. Stevens VL, Hoover E, Wang Y, Zanetti KA. Pre-analytical factors that affect metabolite stability in human urine, plasma, and serum: a review. Metabolites. 2019;9(8):156. doi:10.3390/metabo9080156
20. Schroeder A, Mueller O, Stocker S, et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol. 2006;7:3. doi:10.1186/1471-2199-7-3
21. Geyer PE, Holdt LM, Teupser D, Mann M. Revisiting biomarker discovery by plasma proteomics. Mol Syst Biol. 2017;13(9):942. doi:10.15252/msb.20156297
22. Fliniaux O, Gaillard G, Lion A, Cailleu D, Mesnard F, Betsou F. Influence of common preanalytical variations on the metabolic profile of serum samples in biobanks. J Biomol NMR. 2011;51(4):457-465. doi:10.1007/s10858-011-9574-5
23. Cristiano S, Leal A, Phallen J, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019;570(7761):385-389. doi:10.1038/s41586-019-1272-6
24. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136-1152. doi:10.1056/NEJMra1406184
25. Grimwade D, Ivey A, Huntly BJP. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127(1):29-41. doi:10.1182/blood-2015-07-604496
26. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-1023. doi:10.1056/NEJMra041809
27. Lippi G, Caputo M, Banfi G, Buttarello M, Cerotti F, Daves M. Recommendations for detection and management of unsuitable samples in clinical laboratories. Clin Chem Lab Med. 2007;45(6):728-736. doi:10.1515/CCLM.2007.174
28. Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223-238. doi:10.1038/nrc.2017.7
29. Gainotti S, Mascalzoni D, Bros-Facer V, et al. Meeting patients’ right to the correct diagnosis: ongoing international initiatives on undiagnosed rare diseases and ethical and social issues. Int J Environ Res Public Health. 2018;15(10):2072. doi:10.3390/ijerph15102072
30. Boycott KM, Rath A, Chong JX, et al. International cooperation to enable the diagnosis of all rare genetic diseases. Am J Hum Genet. 2017;100(5):695-705. doi:10.1016/j.ajhg.2017.04.003
31. Haendel MA, Chute CG, Robinson PN. Classification, ontology, and precision medicine. N Engl J Med. 2018;379(15):1452-1462. doi:10.1056/NEJMra1615014
32. Austin CP, Cutillo CM, Lau LPL, et al. Future of rare diseases research 2017-2027: an IRDiRC perspective. Clin Transl Sci. 2018;11(1):21-27. doi:10.1111/cts.12500
33. Thompson R, Johnston L, Taruscio D, et al. RD-Connect: an integrated platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research. J Gen Intern Med. 2014;29(Suppl 3):S780-S787. doi:10.1007/s11606-014-2908-8
34. Dunn WB, Wilson ID, Nicholls AW, Broadhurst D. The importance of experimental design and QC samples in large-scale and MS-driven untargeted metabolomic studies of humans. Bioanalysis. 2012;4(18):2249-2264. doi:10.4155/bio.12.204
35. Hewitt SM, Lewis FA, Cao Y, et al. Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med. 2008;132(12):1929-1935. doi:10.5858/132.12.1929
36. Lazar C, Meganck S, Taminau J, et al. Batch effect removal methods for microarray gene expression data integration: a survey. Brief Bioinform. 2013;14(4):469-490. doi:10.1093/bib/bbs037
37. Henderson GE, Cadigan RJ, Edwards TP, et al. Characterizing biobank organizations in the US: results from a national survey. Genome Med. 2013;5(1):3. doi:10.1186/gm407
38. Coppola L, Cianflone A, Grimaldi AM, et al. Biobanking in health care: evolution and future directions. J Transl Med. 2019;17(1):172. doi:10.1186/s12967-019-1922-3